Zeev's Turnips Patch-No Politics (ZEEV)

[Sam_0]

4:33PM MedImmune lowers guidance (MEDI) 29.18 -0.61: Co lowers its Q3 guidance to a cash loss per share of $0.15-$0.16, vs consensus of a loss of $0.12; cash EPS for 2002 is expected to be $0.62-$0.67; co says its change in financial outlook is due to costs associated with the in-licensing of the human metapneumovirus research program and an increase in R&D costs; also, co says that "in the event FluMist is not approved and launched in 2002, $0.25-$0.27 per share would need to be deducted from cash and GAAP EPS guidance".


Is this one you follow...?